Letter to the editor: intratympanic gentamicin for Ménière’s disease: is there a selective vestibulotoxic effect?

In a recent issue of the European Archives of Otorhinolaryngology journal, Molnár et al. presented an interesting work in which the authors investigated the efectiveness and safety of intratympanic (IT) gentamicin in patients afected by Meniere’s disease (MD) based on the vertigo diaries and pure tone audiogram results. The authors showed that patients afected by MD treated with low dose IT gentamicin (8 mg) had an improvement of vertigo attacks without developing a higher risk of hearing loss. The article is very interesting; however, we have a few comments on the treatment protocol for IT gentamicin proposed by the authors and the role of quantitative vestibular tests in evaluating vestibular functions after gentamicin administration.